<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pneumocystis carinii <z:hpo ids='HP_0002090'>pneumonia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e>) is a life-threatening but preventable <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> that may occur after bone marrow transplantation (BMT) </plain></SENT>
<SENT sid="1" pm="."><plain>Although various prophylactic regimens have been used in this setting to prevent active <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, their efficacy, toxicity profile, and impact on outcomes are poorly described in this patient group </plain></SENT>
<SENT sid="2" pm="."><plain>We undertook a retrospective cohort study in which we reviewed the records of 451 adult patients who underwent BMT for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> over a 7-year period at the Brigham and Women's Hospital </plain></SENT>
<SENT sid="3" pm="."><plain>Post-BMT <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e> prophylaxis consisted of aerosolized <z:chebi fb="4" ids="45081">pentamidine</z:chebi> (AP) 150 mg every 2 weeks or 300 mg per month, <z:chebi fb="0" ids="45924">trimethoprim</z:chebi>/<z:chebi fb="0" ids="9332">sulfamethoxazole</z:chebi> (<z:chebi fb="5" ids="46324,9533">TMP</z:chebi>/<z:chebi fb="0" ids="9332">SMX</z:chebi>) 160/800 mg orally b.i.d </plain></SENT>
<SENT sid="4" pm="."><plain>3 times per week, or dapsone 100 mg orally each day </plain></SENT>
<SENT sid="5" pm="."><plain>Prophylaxis was continued for 1 year post-BMT in <z:hpo ids='HP_0000001'>all</z:hpo> patients when clinically feasible </plain></SENT>
<SENT sid="6" pm="."><plain>One hundred twenty-one patients were unevaluable because of <z:hpo ids='HP_0011420'>death</z:hpo> or relapse &lt;60 days after BMT (n = 89), loss to follow-up upon hospital discharge (n = 20), or other reasons (n = 12) </plain></SENT>
<SENT sid="7" pm="."><plain>Three eligible patients did not receive any prophylaxis and were not further evaluated </plain></SENT>
<SENT sid="8" pm="."><plain>Of the 327 patients analyzed, 133 underwent autologous BMT, 4 syngeneic BMT, 159 related allogeneic BMT, and 31 unrelated allogeneic BMT </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> prophylaxis in the 190 patients receiving allogeneic BMT consisted of T-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> with anti-CD5 and complement in 58 patients and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>/<z:chebi fb="0" ids="44185">methotrexate</z:chebi> or FK506 with or without steroids in 132 patients </plain></SENT>
<SENT sid="10" pm="."><plain>Eight of 327 (2.4%) documented <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e> cases were identified, 0 of 105 in patients receiving only <z:chebi fb="5" ids="46324,9533">TMP</z:chebi>/<z:chebi fb="0" ids="9332">SMX</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>Four cases occurred in patients receiving only AP (4/44, 9.1%; odds ratio [OR] relative to <z:chebi fb="5" ids="46324,9533">TMP</z:chebi>/<z:chebi fb="0" ids="9332">SMX</z:chebi> 23.4, 95% confidence interval [CI] 1.2, 445.2); 1 in patients receiving only dapsone (1/31, 3.2%; OR not significant); 2 in patients receiving more than 1 prophylactic regimen (2/147 1.4%; OR not significant); and 1 &gt;1 year post-BMT in a patient who was off <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e> prophylaxis </plain></SENT>
<SENT sid="12" pm="."><plain>Although the patients receiving only AP had a significantly lower probability of treatment-related toxicity than those receiving <z:chebi fb="5" ids="46324,9533">TMP</z:chebi>/<z:chebi fb="0" ids="9332">SMX</z:chebi> (OR 0.19 [95% CI 0.04, 0.851), the probability of their acquiring other serious non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> was increased (OR 2.2 [95% CI 1.0, 4.6]), and the probability of their dying by 1 year post-BMT was significantly higher (OR 5.2 [95% CI 2.4, 26.6]), even when adjusted for variables such as type of BMT (autologous versus allogeneic; high versus low risk) and sex </plain></SENT>
<SENT sid="13" pm="."><plain>Although AP is associated with fewer toxicities, the data show that it is inferior to <z:chebi fb="5" ids="46324,9533">TMP</z:chebi>/<z:chebi fb="0" ids="9332">SMX</z:chebi> in preventing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e> in the post-BMT setting and is associated with an increased risk of other <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> and a higher mortality at 1 year after BMT </plain></SENT>
</text></document>